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Figure 2. Highest Toxicity Level Across All Body Symptoms (fever in the
absence of signs of infection. fatigue, skin rash, local reactions, nausea, vom-
iting, anorexia, insomnia, dizziness, and syncope) experienced by PBSC donors,
by unrelated vs. related donors, at baseline, donation, and 1 year post-
donation.
Abstracts / Biol Blood Marrow Transplant 21 (2015) S30eS53S42donation-related grade 2-4 pain, grade 3-4 pain, and grade 2-
4 MTC (Table 2) compared to URDs of PBSC. In addition, RDs
of PBSC were less likely than URDs of PBSC to return to
baseline levels of pain and MTC at 1 year. Although only a
small fraction of both URDs and RDs reported grade 2-4
pain/MTC 1 year post-donation (Table 1), RDs were 2-3
times more likely to report pain/MTC at 1 year than URDs.
Conclusions: RDs of PBSC have more baseline and donation-
related pain/MTC and less complete 1 year recovery than
URDs. Ongoing analysis of baseline health status of RDs on
the RDSafe trial is underway to further deﬁne differences
between RDs/URDs that could account for these higher levels
of pain/MTC.Fig. 1. CD8 cell dose and overall survival.21
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Peripheral blood stem cells (PBSC) are the major source for
allogeneic stem cell transplantations. It has been shown that
treatment with 7.5 mg/kg G-CSF for 5 days is sufﬁcient to
mobilize and collect required CD34+ cells for transplantation.
However, uncertainty remains in 0.5e5.0% of all donors
regarding insufﬁcient mobilization. In this retrospective
analysis we evaluated 5691 allogeneic stem cell mobilization
regimens (72% male vs. 28% female donors) from two major
collection centers focusing on donor risk factors for poor
mobilization. According to our historical reciprocal weight
and BMI-adapted mobilization protocol low weight/low BMI
donors received > 8.3mg/kg/d for 4 days, whereas overweight
donors received <7.5 mg/kg. At day 5 all donors received
526mg G-CSF 2 hours before apheresis. In total, a mean G-CSF-
dosis of 8.9  1.0mg/kg/d for 5 days has been utilized (min
4.5mg/kg/d e max. 15.9mg/kg/d). Mean CD34+ cell concentra-
tion of 95 49/ml could be achieved in the peripheral blood at
day 5 before starting apheresis. This enabled us to collect amean of 9.7  8.0 CD34+ cells/kg body weight recipient cor-
responding to 658  252 million total CD34+ cells in the
product. In 96.3% of all cases one single apheresis was sufﬁ-
cient to collect the requested amount of CD34+ cells. Using
logistic regression analysis we deﬁned female sex, low BMI
and low platelet (PLT) count at baseline as strongest risk fac-
tors for poor mobilization. Low white blood cell (WBC) con-
centration, low hematocrit and G-CSF-doses < 9mg/kg/d were
also signiﬁcantly associated with poor mobilization. Using the
strongest numeric predictors (BMI, PLT) we employed STEPP-
analysis to establish a statistically signiﬁcant cross table risk
score, that allows prediction of CD34+ cells in the peripheral
blood at day 5 according to baseline PLT and BMI. From lowest
cumulative risk score 2 (PLT>290; BMI>34.5) to highest risk
score 6 (PLT<170; BMI<20.7) differences between all risk
scoreswere highly signiﬁcant. Interestingly, subgroup analysis
demonstrated that female but not male donors with poor risk
score that received > 9mg/kg/d G-CSF could improve signiﬁ-
cantly mobilization outcome without further side effects.
Thus, overall results demonstrated that weight adapted G-CSF
dosage for allogeneic donor treatment may improve mobili-
zation outcome, i.e. in poor risk prospect female donors with
low BMI and low PLT at baseline. Further genetic analysis may
identify factors responsible for mobilization outcome.22
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Background: Younger donor age is associated with better
survival in unrelated donor bone marrow transplants, but
young unrelated donors have not shown an overall survival
